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Abstract
Introduction
Critical limb ischemia (CLI) is the most severe manifesta-
tion of peripheral artery disease (PAD), is associated with 
high rates of myocardial infarction, stroke, and amputa-
tion, and has a high health economic cost. The objective 
of this study was to estimate the incidence of lower limb 
amputation, the most serious consequence of CLI, and to 
create a surveillance methodology for the incidence of isch-
emic amputation in Minnesota.
Methods
We assessed the incidence of ischemic amputation using 
all inpatient hospital discharge claims in Minnesota from 
2005 through 2008. We identified major and minor isch-
emic amputations via the International Classification of 
Diseases, 9th Revision, Clinical Modification (ICD-9-CM) 
procedure codes for lower limb amputation not due to trau-
ma or cancer and assessed geographic and demographic 
differences in the incidence of ischemic amputation.
Results
The age-adjusted annual incidence of lower limb ischemic 
amputation in Minnesota during the 4-year period was 
20.0  per  100,000  (95%  confidence  interval,  19.4-20.6). 
Amputations increased significantly with age, were more 
common in men and in people with diabetes, and were 
slightly more common in rural residents. The number of 
amputation-related  hospitalizations  was  steady  over  4 
years. The median total charge for each amputation was 
$32,129, and cumulative inpatient hospitalization charges 
were $56.5 million in 2008.
Conclusion
The incidence of ischemic amputation is high and results 
in  major  illness  and  health  economic  costs.  These  data 
represent the first population-based estimate of ischemic 
amputation at the state level and provide a national model 
for state-based surveillance.
Introduction
Lower extremity peripheral artery disease (PAD) is defined 
as blockages in the major arteries that supply the leg (1,2). 
PAD is 1 of the 3 major systemic atherosclerotic diseases 
and  has  a  prevalence  similar  to  that  of  coronary  heart 
disease  and  ischemic  stroke. People  with  PAD  may  be 
asymptomatic  but  often  experience  claudication  as  the 
primary  ischemic  symptom  that  causes  exertional  leg 
muscle pain. When atherosclerotic artery blockages in the 
leg progress and become severe or when a clot travels to 
completely block a leg artery (arterial thromboembolism), 
unremitting ischemia at rest can occur. This presentation 
of PAD is defined as critical limb ischemia (CLI) and sig-
nifies an imminent risk of amputation if revascularization 
is not achieved. The etiology of more than 80% of amputa-
tions that occur in all developed nations, including those 
that occur in people with diabetes, are due to PAD and CLI 
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(3). The incidence of CLI will likely increase as the popula-
tion ages because of the increasing prevalence of diabetes. 
If so, these preventable, morbid, and costly limb ischemic 
events will demand greater medical and revascularization 
resources (4). This burden has an effect at the family, city, 
and state levels.
Major lower extremity amputation occurs at an estimated 
rate of 120 to 500 per million per year in Western countries 
(5), and this rate increases with age (6). The rate is estimat-
ed at 25% in patients with CLI (1,2). Ischemic amputation is 
still a commonly performed operation, even in hospitals that 
emphasize  aggressive  revascularization  for  limb  salvage, 
and occurs more often in the United States among blacks 
than  whites  (7).  The  age-adjusted  annual  rate  of  lower 
extremity amputation in the United States was reported 
to remain stable at approximately 30 per 100,000 per year 
from 1979 to 1989, despite an increase in the annual rate 
of percutaneous transluminal angioplasty and peripheral 
bypass surgery (8). Hallett et al reported a decrease in the 
rate of major (but not minor) lower extremity amputation 
(from 36.7 to 19.0 per 100,000 annually from 1973 to 1992), 
while the rate of percutaneous and operative revascular-
ization increased during the same period (6). More recent 
data from Goodney et al suggest a decrease in major lower 
extremity  amputation  rates  and  lower  extremity  bypass 
surgery, with an associated increase in rates of endovas-
cular procedures in older adults (9). These conflicting esti-
mates use different case ascertainment strategies, and we 
are not aware of any effort in North America or Europe to 
conduct surveillance of ischemic amputation rates.
The aim of this investigation was to create a surveillance 
methodology for the incidence of ischemic amputation in 
Minnesota and to identify potential geographic and demo-
graphic  disparities  in  incidence.  This  method  was  also 
designed to permit creation of a conservative estimate of 
the  direct  costs  and  health  economic  burden  associated 
with ischemic amputation at the state level. We hypothe-
sized that there would be heterogeneity in ischemic ampu-
tation rates on the basis of geographic regions (eg, urban 
vs  rural);  that  ischemic  amputation  would  represent  a 
significant cardiovascular disease burden compared with 
both coronary heart disease (CHD) and stroke mortality; 
that hospital-related charges and costs would be compa-
rable to those for CHD and stroke; and that trends in the 
incidence of amputation may be evident during a 4-year 
surveillance period. We intended to close a knowledge gap 
on ischemic amputation and describe a surveillance strat-
egy that could be modeled by other states.
Methods
We used data from a claims-based administrative data set 
compiled annually by the Minnesota Hospital Association, 
using the Uniform Billing Code of 1992 and the Uniform 
Billing Code of 2004 established by the National Uniform 
Billing Committee. This claims dataset contains informa-
tion on inpatient hospitalizations at participating hospi-
tals  in  Minnesota,  including  approximately  97%  of  the 
staffed inpatient beds at acute care hospitals. Information 
on Minnesota residents hospitalized outside the state was 
limited  to  the  bordering  states  of  North  Dakota,  South 
Dakota,  and  Iowa;  information  on  hospitalizations  in 
neighboring  Wisconsin  was  not  available.  We  used  dis-
charges that took place from January 1, 2005, through 
December  31,  2008.  The  dataset  includes  disease  and 
procedure  codes  from  the  International  Classification 
of  Diseases,  9th  Revision,  Clinical  Modification  (ICD-9-
CM), and patient sex, age, residential zip code, county of 
residence, date of admission, date of discharge, payer type, 
total dollar charges, and discharge disposition.
We identified lower limb amputations through ICD-9-CM 
codes. For each hospitalization record, up to 24 disease 
codes and 8 procedure codes are present. We first identi-
fied hospitalizations with any diabetes or cardiovascular 
disease code in the primary or secondary positions (ICD-
9-CM  250.xx  or  390.xx-459.xx),  excluding  patients  with 
an  injury  code  in  the  primary  position  (ICD-9-CM  800.
xx-999.xx). We then identified lower limb ischemic ampu-
tations by ICD-9-CM procedure codes for lower extremity 
amputation (ICD-9-CM 84.10-84.19), excluding cases with 
an  ICD-9-CM  disease  code  for  cancer  (including  malig-
nant neoplasm of the bone, malignant neoplasm of skin, 
melanoma, and Kaposi’s sarcoma). We further classified 
amputations as major (at or above the ankle) or minor 
(below the ankle). For comparison, we also identified CHD, 
stroke,  and  transient  ischemic  attack  (TIA)  hospitaliza-
tions by the presence of ICD-9-CM disease codes 410.xx-
414.xx (CHD) and 430.xx-438.xx (stroke and TIA) in the 
primary position.
To  estimate  the  total  costs  for  each  hospitalization,  we 
adjusted  total  dollar  charges  by  the  hospital-specific 
cost-to-charge ratio at the time of patient discharge. For 
hospitalizations at facilities with no cost-to-charge ratio, 
depending on the hospital’s location, we used the aver-
age rural hospital or urban hospital ratio for the state. 
Hospitalizations in South Dakota (n = 69) were not identi-
fied by facility, so we substituted the urban hospital cost-VOLUME 8: NO. 6
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to-charge ratio, on the basis of known patterns of care for 
Minnesota residents hospitalized in that state. We applied 
this adjustment to estimate the total resource cost associ-
ated with inpatient care only, as it does not reflect costs 
associated with out-of-hospital imaging, procedures, office-
based care, outpatient rehabilitation, or use of limb pros-
theses or chronic medications (10-17). To account for price 
inflation, we adjusted all cost values using the US Bureau 
of  Labor  Statistics  Consumer  Price  Index  for  Inpatient 
Hospital Services (18).
We calculated the population at risk by county, sex, age 
group (0-4 y, 5-14 y, 15-24 y, 25-34 y, 35-44 y, 45-54 y, 55-
64 y, 65-74 y, 75-84 y, and ≥85 y), and year of discharge 
using  vintage  2008  bridged-race  postcensus  population 
estimates of Minnesota supplied by the US Census Bureau 
and National Center for Health Statistics (19). The age-
adjusted  incidence  of  lower  limb  ischemic  amputation 
was calculated using these annual population estimates 
and the number of hospitalizations during 4 consecutive 
years. We suppressed counts for counties with fewer than 
11 total cases.
We defined urban residence as living in counties that were 
part of Metropolitan Statistical Areas as defined by the US 
Census Bureau in 2007; all other counties were classified 
as rural (20). The urban counties included approximately 
72% of the total state population (approximately 5.2 mil-
lion) from 2005 through 2008.
Continuous data are presented as medians (interquartile 
range); categorical data are presented as frequencies. Both 
inpatient hospitalization charges and costs are presented 
using medians, means, and sums. All analyses were con-
ducted using SAS software version 9.2 (SAS Institute, Inc, 
Cary, North Carolina).
Results
There were 4,302 hospitalizations for lower limb amputa-
tions among Minnesotans from 2005 through 2008 (Table 
1). Of these, 1,831 (43%) were major, 2,470 (57%) were 
minor, and 1 was unspecified. The median patient age was 
67, and major amputations were more likely to occur in 
older people. Most amputations took place among men and 
people who lived in an urban county. Of total amputations, 
72% of cases were performed in people with diabetes, most 
of whom had a minor amputation.
The age-adjusted annual incidence of lower limb ischemic 
amputation in Minnesota during the 4-year period was 
20.0 per 100,000 (95% confidence interval [CI], 19.4-20.6), 
which is more than half the annual stroke mortality (38.3 
per 100,000; 95% CI, 37.5-39.1) and comparable to mortal-
ity for both diabetes (20.8 per 100,000; 95% CI, 20.2-21.4) 
and Alzheimer’s disease (21.6 per 100,000; 95% CI, 21.0-
22.2) (21). The figure illustrates the lower limb ischemic 
amputation  incidence,  CHD  mortality  rate,  and  stroke 
mortality rates by county in Minnesota from 2005 through 
2008.  Counties  in  the  highest  quartile  of  age-adjusted 
ischemic  amputation  incidence  are  concentrated  in  the 
northern half of the state, along with groups of counties 
in the southwest and southeast; all but 2 are rural. The 
annual incidence of ischemic amputation in rural counties 
is 21.4 per 100,000 (95% CI, 20.3-22.5), approximately 9% 
higher than in urban counties (19.6 per 100,000, 95% CI, 
18.8-20.3). The overall pattern is similar to that for CHD 
mortality and to a lesser degree similar to that for stroke 
mortality.
Figure. Lower limb ischemic amputations, coronary heart disease (CHD) 
mortality, and stroke mortality per 100,000 by Minnesota county, 2005-
2008. Data for lower limb ischemic amputations obtained from Minnesota 
Hospital Uniform Billing Claims Data; Health Economics Program, Minnesota 
Department of Health; and the Minnesota Hospital Association. Data for CHD 
mortality obtained from Minnesota Department of Health Center for Health 
Statistics and International Classification of Diseases, 10th revision (ICD-10) 
codes I00-I09, I11, I13,and I20-I51. Data for stroke mortality obtained from 
Minnesota Department of Health Center for Health Statistics and ICD-10 
codes I60-I69.
The number of CHD hospitalizations declined during the 
study period, while the number of ischemic amputations and 
stroke hospitalizations were steady (Table 2). The median 
charge for ischemic amputation hospitalizations was similar 
to that for CHD and about twice as high as for stroke and TIA 
hospitalizations. The total direct inpatient hospital charges VOLUME 8: NO. 6
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for  all  ischemic  amputation  hospitalizations  approached 
20% of the total charges for stroke and TIA.
The inflation-adjusted estimated median cost for ischemic 
amputation remained stable from 2005 through 2008, but 
the mean cost per hospitalization increased by 9.2% (Table 
3). Compared with 2005, the number of annual events in 
2008 was 11.5% lower, and total annual inflation-adjusted 
inpatient hospital costs were 3.8% lower. The pattern in 
the intervening years was not monotonic.
Discussion
We used a representative hospital discharge data set from 
2005 through 2008 to evaluate the incidence of ischemic 
amputation in Minnesota. These data demonstrated that 
most patients who underwent ischemic amputation were 
male  and  older.  The  age-adjusted  annual  incidence  of 
ischemic  amputation  in  Minnesota  was  low  compared 
with the incidence reported elsewhere (6,8). Diabetes was 
prevalent in people who underwent ischemic amputation; 
72% of the total ischemic amputation population had dia-
betes, and 63% of patients who had a major amputation 
had diabetes. Other studies have reported a prevalence 
of diabetes in ischemic amputees that ranges from 45% 
to 61% (22,23). Furthermore, we found that the resource 
allocation  by  hospitals  and  economic  burden  was  high; 
people  who  underwent  ischemic  amputation  had  long 
hospital stays. Median inpatient hospitalization charges 
were similar to those for CHD patients and double those 
for stroke and TIA patients.
Though the systemic atherosclerosis disease process pro-
vides a common etiology for stroke, myocardial infarction, 
and PAD, and though systemic risk is elevated for people 
with each of these syndromes, the incidence of amputation, 
CHD  mortality,  and  stroke  mortality  were  not  uniform 
across Minnesota. This finding likely reflects differing care 
standards for each condition, because reporting for each 
condition is likely to be similar (each outcome represents 
a “hard ischemic endpoint”). These data do not provide 
insight  into  distinctions  in  the  process  of  care  between 
coronary and stroke or CLI patients that may clarify these 
varying rates. Our results underscore — on a state-based 
and county-based level — the health disparity in care that 
affects the CLI population.
Visser et al estimated a cost of $45,200 for a major amputa-
tion in the first year, followed by an annual cost of $11,000 
beyond the initial hospitalization (24). In a more selected 
population of patients treated for CLI, the immediate cost 
directly  attributed  to  amputation  was  $40,000  (1).  The 
addition of subsequent rehabilitation is usually associated 
with a doubling of these costs (1). Our cost findings in a 
more  general  population  provide  additional  information 
about immediate hospitalization charges associated with 
ischemic amputation. The Healthcare Cost and Utilization 
Project Nationwide Inpatient Sample of 39.5 million dis-
charges in the United States in 2007 estimated median 
charges for amputation due to “circulatory system disor-
ders” (exclusive of the upper limb and toe) of $45,900 and 
median hospital costs of $15,900 (25). This value compares 
well with our estimates.
Minnesota is home to less than 2% of the total US popu-
lation  (19),  and  Minnesotans  experience  lower  rates  of 
atherosclerotic  disease  and  lower  medical  costs  than 
the  national  average  (26-28).  Nevertheless,  our  results 
delineate  the  health  cost  implications  in  the  context  of 
nationally limited health care resources. Ziegler-Graham 
et al estimated the prevalence of limb loss in the United 
States, projected these values through the year 2030, and 
suggested that ischemic limb loss is likely to rise with the 
aging population and an increase in diabetes and “dysvas-
cular” disease (29).
Differences in ischemic amputation rates in the literature 
may be due to the unique populations included in those 
distinct datasets, differing case identification criteria for 
ischemic  amputation,  inclusion  or  exclusion  of  minor 
amputations  or  people  with  diabetes,  inclusion  of  first 
amputation  events  versus  cumulative  per-patient  event 
rates, or multiple amputations in the ipsilateral limb. Only 
through use of a consistent methodology will patients, pay-
ers, departments of health, and other agencies be able to 
make state-to-state comparisons. Consistent application of 
a common cross-state case ascertainment strategy would 
foster creation of estimates of the incidence of lower limb 
ischemic  amputation  and  costs,  permitting  future  com-
parison of population-based treatment strategies. Although 
racial and ethnic disparities in amputation rates have been 
elucidated, disparities based on geography, sex, and health 
care  coverage  may  become  visible  from  regional  data. 
Health disparities, once revealed, provide an opportunity 
to implement preventive health strategies that can reduce 
high ischemic amputation rates across and within states.
Despite the use of a representative hospital discharge data 
set, this study had several limitations. The limited avail-VOLUME 8: NO. 6
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ability of clinical covariates in public data sets is acknowl-
edged in the literature (30). Multiple hospitalizations for 
amputation (of the same or different limb) cannot be iden-
tified because of the absence of unique patient identifiers. 
Another limitation is that inpatient hospitalization charg-
es,  and  the  subsequent  adjustment  with  cost-to-charge 
ratios, do not optimally reflect the resources expended in 
managing this condition. These data do not distinguish 
between use of health care resources that were expended 
to treat the episode of CLI versus any associated illnesses 
that existed during the index hospitalization. Additionally, 
these charges only reflect resources expended during the 
inpatient  hospitalization  and  do  not  reflect  costs  after 
discharge. Our cost estimate is conservative, as it does not 
reflect any ongoing disability costs associated with isch-
emic amputation. Furthermore, data for counties with few 
cases of ischemic amputation (ie, 11-20) were reported, but 
the estimates are potentially unstable and should be inter-
preted with caution. Finally, our results were derived from 
a state that is known to be characterized by lower racial 
and  ethnic  diversity  than  the  nation.  Therefore,  these 
data are not presumed to be generalizable to other states 
or regions. Despite these limitations, these data provide 
insight into the incidence and cost of ischemic amputation 
in Minnesota.
In  conclusion,  these  data  provide  the  first  contempo-
rary  population-based  estimate  of  ischemic  amputation 
and hospitalization charges in a nonselected state-based 
population. Although the incidence of ischemic amputa-
tion in Minnesota is lower than has been reported from 
other studies, the direct inpatient hospital charges and 
estimated costs are high. The incidence of ischemic ampu-
tation was higher in rural counties. Ischemic amputation 
represents a significant statewide cardiovascular disease 
burden compared with both CHD and stroke mortality. 
This methodology could underpin an ischemic amputation 
surveillance strategy that could be modeled by other states 
nationally.
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Tables
Table 1. Population Characteristics of Ischemic Amputations in Minnesota, 2005-2008a
Characteristic
All Amputations 
(n = 4,302)
Minor Amputations 
(n = 2,470)
Major Amputations 
(n = 1,831)
Age, median (IQR), y 6 (56-9) 65 (54-6) 0 (59-81)
Male sex, % 65.4 6.5 62.5
Urban county residence, % 65.1 66.0 63.9
Diabetes, % 2.3 9.4 62.8
Length of stay, median (IQR), d  (4-12) 6 (4-10) 9 (6-14)
Inpatient charges, median (IQR), $ 32,129 (1,980-5,61) 2,3 (16,08-4,3) 39,512 (21,414-3,14)
Inpatient hospitalization costs, median (IQR), $ 12,434 (,402-21,14) 10,609 (6,525-18,12) 15,246 (8,992-26,912)
 
Abbreviation: IQR, interquartile range. 
a A minor amputation is any amputation below the ankle, and a major amputation is any amputation at or above the ankle; 1 amputation was at an unspeci-
fied site.VOLUME 8: NO. 6
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Table 2. Inflation-Adjusted Direct Inpatient Hospital Charges for Ischemic Amputation, Coronary Heart Disease, and Stroke in 
Minnesota, 2005-2008a
Condition 2005 2006 2007 2008
Ischemic amputation
Mean, $ 51,952 55,521 55,52 55,311
Median, $ 35,069 3,456 33,22 35,893
Total, $ 59,849,292 61,684,119 56,40,502 56,528,330
Hospitalizations, n 1,152 1,111 1,01 1,022
Coronary heart diseaseb
Mean, $ 43,280 40,412 41,924 40,999
Median, $ 34,954 33,02 34,213 33,321
Total, $ 1,108,61,561 991,833,92 924,145,45 86,268,816
Hospitalizations, n 25,616 24,543 22,043 21,33
Stroke and transient ischemic attackc
Mean, $ 29,008 2,06 29,361 29,09
Median, $ 18,13 16,91 1,921 1,831
Total, $ 351,641,640 336,098,550 338,32,622 349,819,464
Hospitalizations, n 12,122 12,131 11,523 11,5
 
Abbreviation: ICD-9-CM, International Classification of Diseases, 9th Revision, Clinical Modification. 
a All charges are inflated to 2008 $US using the Consumer Price Index for inpatient hospital care. 
b Coronary heart disease hospitalizations, primary ICD-9-CM disease code, 410-414. 
c Stroke and transient ischemic attack hospitalizations, primary ICD-9-CM disease code, 430-438.
Table 3. Inflation-Adjusted Inpatient Hospital Costs for Ischemic Amputation in Minnesota, 2005-2008a
Estimated Inpatient Hospital Cost 2005 2006 2007 2008
Mean, $ 19,230 21,163 20,90 21,015
Median, $ 13,852 14,83 12,829 13,466
Total, $ 22,240,233 23,469,22 21,102,51 21,393,668
Hospitalizations with estimable costs, n 1,150 1,109 1,015 1,018
 
a Costs calculated from hospital-specific cost-to-charge ratios in effect at time of patient discharge. All cost values are inflated to 2008 $US using the 
Consumer Price Index for inpatient hospital care.